Form 4: Sensei Biotherapeutics Executive Granted Stock Options

Stephanie Krebs, Chief Business Officer of Sensei Biotherapeutics, received stock options for 120,000 shares on February 14, 2025.

Summary

• Stephanie Krebs, the Chief Business Officer of Sensei Biotherapeutics, was granted stock options on February 14, 2025.
• The options are for 120,000 shares of Sensei Biotherapeutics common stock.
• The exercise price of the options is $0.476 per share.
• The options vest over four years, with 25% vesting on February 14, 2026, and the remainder vesting monthly over the following three years, contingent upon continuous service with the Issuer.

Sentiment

Score: 7

Explanation: The document reflects a standard executive compensation practice, indicating stability and alignment of interests. It's a neutral-positive event.

Positives

• The granting of stock options aligns the executive's interests with those of the shareholders.
• The vesting schedule incentivizes long-term commitment from the Chief Business Officer.

Future Outlook

The document does not contain specific forward-looking statements beyond the vesting schedule of the stock options.

Industry Context

Stock options are a common form of executive compensation in the biopharmaceutical industry, used to attract and retain talent and align their interests with company performance.

Comparison to Industry Standards

• Stock option grants are a standard component of compensation packages for executives in biotech companies like Sensei Biotherapeutics.
• Companies such as Amgen, Gilead Sciences, and Biogen routinely use stock options as part of their executive compensation plans.
• The vesting schedule of four years is also typical in the industry, aligning with long-term strategic goals.

Stakeholder Impact

• Shareholders may view the stock option grant as a positive incentive for the Chief Business Officer to drive company growth.
• Employees may see this as a sign of the company's commitment to its leadership team.

Key Dates

Keywords

Sensei Biotherapeutics, stock options, executive compensation, Form 4, SNSE, Stephanie Krebs, Chief Business Officer, vesting